Peter S Hammerman
Overview
Explore the profile of Peter S Hammerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
14843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cotton J, Estrada Diez J, Sagar V, Chen J, Piquet M, Alford J, et al.
Cancer Res
. 2023 Aug;
83(21):3611-3623.
PMID: 37603596
Significance: The evolution and heterogeneity of EGFR inhibitor tolerance are identified in a large number of clones at enhanced cellular and temporal resolution using an expressed barcode technology coupled with...
2.
Togami K, Chung S, Madan V, Booth C, Kenyon C, Cabal-Hierro L, et al.
Cancer Discov
. 2021 Oct;
12(2):522-541.
PMID: 34615655
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia of plasmacytoid dendritic cells (pDC). BPDCN occurs at least three times more frequently in men than in women, but the...
3.
Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, et al.
Nat Cancer
. 2021 Jun;
2(5):503-514.
PMID: 34142094
No abstract available.
4.
Wang H, Mulford I, Sharp F, Liang J, Kurtulus S, Trabucco G, et al.
Cancer Res
. 2021 Jan;
81(11):3079-3091.
PMID: 33504557
p53 is a transcription factor that plays a central role in guarding the genomic stability of cells through cell-cycle arrest or induction of apoptosis. However, the effects of p53 in...
5.
Monaco K, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, et al.
Clin Cancer Res
. 2020 Dec;
27(7):2061-2073.
PMID: 33355204
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled...
6.
Sehgal K, Portell A, Ivanova E, Lizotte P, Mahadevan N, Greene J, et al.
J Clin Invest
. 2020 Nov;
131(2).
PMID: 33151910
Resistance to oncogene-targeted therapies involves discrete drug-tolerant persister cells, originally discovered through in vitro assays. Whether a similar phenomenon limits efficacy of programmed cell death 1 (PD-1) blockade is poorly...
7.
Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G, et al.
Clin Cancer Res
. 2020 Oct;
27(1):342-354.
PMID: 33046519
Purpose: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently feedback activated in...
8.
Lu H, Liu C, Huynh H, Le T, LaMarche M, Mohseni M, et al.
Oncotarget
. 2020 Feb;
11(3):265-281.
PMID: 32076487
SHP2 mediates RAS activation downstream of multiple receptor tyrosine kinases (RTKs) and cancer cell lines dependent on RTKs are in general dependent on SHP2. Profiling of the allosteric SHP2 inhibitor...
9.
Zhang H, Christensen C, Dries R, Oser M, Deng J, Diskin B, et al.
Cancer Cell
. 2019 Dec;
37(1):37-54.e9.
PMID: 31883968
Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription. However, little is known about its impact on genomic instability and cancer immunity. Using a...
10.
Li F, Huang Q, Luster T, Hu H, Zhang H, Ng W, et al.
Cancer Discov
. 2019 Nov;
10(2):270-287.
PMID: 31744829
Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with -mutant lung adenocarcinoma (LUAD) remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune...